Variables
Nephrotoxicity (+) n=106 (62.4%) Nephrotoxicity (-) n=64 (37.6%)
p value
Age, median (min-max) 75 (19-95) 62 (18-92) < 0.001
Sex, n (%) Male Female 53 (50) 53 (50) 45 (70.3) 19 (29.7)
0.009
Duration of hospitalization before COL therapy, median (min-max)
18 (3-101)
14.5 (4-52)
0.109
APACHE II (mean±SD) 25.17±6.8 21.94±7.85 0.007
Underlying Diseases, n (%) Chronic Obstructive Pulmonary Disease (COPD) Diabetes mellitus (DM) Cardiac failure (CF) Coronary artery disease (CAD) Immunosuppression Solid organ malignancy 61 (57.5) 30 (28.3) 24 (22.6) 30 (28.3) 7 (6.6) 3 (2.8) 25 (39.1) 14 (21.9) 9 (14.1) 10 (15.6) 7 (10.9) 1 (1.6) 0.02 0.354 0.171 0.059 0.319 1.0
Initial serum urea (mg/dL) median (min-max) 46 (16-125) 39.5 (9-87) 0.02
Initial serum creatinine (mg/dL) median (min-max) 0.8 (0.34-1.2) 0.63 (0.3-1.2) < 0.001
End-treatment serum urea (mg/dL) median (min-max) 116 (35-295) 43.5 (8-169) < 0.001
End-treatment serum creatinine (mg/dL) median (min-max) 2.46 (0.73-8) 0.72 (0.21-1.5) < 0.001
Concomitant nephrotoxic agent use, n (%) Sulbactam Vancomycin NSAID NSAID+Sulbactam NSAID+Sulbactam+Amikacin ACEI+Sulbactam AG ACEI+ARB AMPHOb Furosemide 78 (73.6) 19 (17.9) 14 (13.2) 3 (2.8) 1 (0.94) 2 (1.9) 1 (0.94) 1 (0.94) 3 (2.8) 1 (0.94) 33 (31.1) 34 (53.1) 6 (9.4) 8 (12.5) 3 (4.7) 1 (1.6) 1 (1.6) 2 (3.1) 1 (1.6) 2 (3.1) 1 (1.6) 9 (14.1) 0.006 0.127 0.894 0.524 0.716 0.876 0.295 0.716 0.912 0.716 0.012
Vasopressor agent use, n (%) 60 (56.6) 26 (40.6) 0.043
14-day mortality, n (%) 50 (47.2) 22 (34.4) 0.102
28-day mortality, n (%) 37 (34.9) 18 (28.1) 0.029
Overall mortality, n (%) 98 (92.5) 44 (68.8) < 0.001